{
    "clinical_study": {
        "@rank": "36946", 
        "arm_group": [
            {
                "arm_group_label": "Once Weekly VRS-317 Administration", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive long-term repeat dosing of subcutaneous VRS-317 once per week."
            }, 
            {
                "arm_group_label": "Semi-Monthly VRS-317 Administration", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive long-term repeat dosing of subcutaneous VRS-317 twice per month."
            }, 
            {
                "arm_group_label": "Once Monthly VRS-317 Administration", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive long-term repeat dosing of subcutaneous VRS-317 once per month."
            }
        ], 
        "brief_summary": {
            "textblock": "Protocol 13VR3 is designed as an open-label extension study assessing long-term VRS-317\n      administration. It is open to subjects completing a Versartis Phase 2 or 3 study in children\n      with growth hormone deficiency.\n\n      Patients will be monitored for safety throughout their participation in the study. Safety\n      will be monitored by physical examination, inspection of injection sites, vital signs and\n      clinical laboratory determinations. Adverse events (AEs) and concomitant medications will be\n      captured. AEs will be coded using CTCAE."
        }, 
        "brief_title": "Versartis Long-Term Extension Study of VRS-317", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Pediatric Growth Hormone Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion of a Versartis Phase 2 or Phase 3 clinical study in pediatric patients\n             with GHD\n\n          -  Willing and able to comply with all study procedures\n\n        Exclusion Criteria:\n\n          -  Withdrawal from a Versartis clinical study in pediatric patients with GHD\n\n          -  Lack of compliance in a Versartis clinical study in pediatric patients with GHD\n\n          -  Use of prohibited medications that may alter responses to the test product\n\n          -  Presence of certain medical condition conditions if condition or treatment of\n             condition may alter response to test product"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068521", 
            "org_study_id": "13VR3"
        }, 
        "intervention": {
            "arm_group_label": [
                "Once Weekly VRS-317 Administration", 
                "Semi-Monthly VRS-317 Administration", 
                "Once Monthly VRS-317 Administration"
            ], 
            "description": "Subcutaneous injection", 
            "intervention_name": "VRS-317", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Growth Hormone Deficiency", 
            "Pediatric Growth Hormone Deficiency", 
            "GHD", 
            "PGHD", 
            "VRS-317", 
            "Versartis", 
            "Growth disorder", 
            "Long acting growth hormone", 
            "Growth hormone", 
            "Weekly growth hormone dosing", 
            "Semi-monthly growth hormone dosing", 
            "Monthly growth hormone dosing", 
            "IGF-I", 
            "Short stature", 
            "Height velocity", 
            "Annual height velocity", 
            "Growth rate"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "link": {
            "description": "Versartis website", 
            "url": "http://versartis.com"
        }, 
        "location": {
            "contact": {
                "email": "ehumphriss@versartis.com", 
                "last_name": "Eric Humphriss", 
                "phone": "650-963-8587"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-Label, Long-Term Extension Study of the Safety and Efficacy of A Long-acting Human Growth Hormone (VRS-317) in Children With Growth Hormone Deficiency", 
        "other_outcome": {
            "description": "PK/PD peak and trough measurements will be assessed throughout the study with assessment of plasma VRS-317 concentrations and IGF-I and its binding proteins measured at pre-specified time points.", 
            "measure": "Pharmacokinetics and pharmacodynamics (PK/PD)", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1, Month 3, 6 and 12"
        }, 
        "overall_contact": {
            "email": "ehumphriss@versartis.com", 
            "last_name": "Eric Humphriss, MBA", 
            "phone": "650-963-8587"
        }, 
        "overall_contact_backup": {
            "email": "gbright@versartis.com", 
            "last_name": "George Bright, MD", 
            "phone": "650-963-8589"
        }, 
        "overall_official": {
            "affiliation": "Versartis Inc.", 
            "last_name": "George Bright, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will have quarterly (every 3 months) in clinic visits throughout the study for up to 4 years. Safety assessments include recording of adverse events and concomitant medications, monitoring of injection sites, vital signs and clinical laboratory determinations.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Quarterly visits for up to 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068521"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Efficacy will be assessed by annual height velocity (cm/yr) in the first year of cumulative treatment (first 12 months) and at each subsequent 12 month interval for up to 4 years.", 
            "measure": "Annual Height Velocity", 
            "safety_issue": "No", 
            "time_frame": "Annual assessments for up to 4 years"
        }, 
        "source": "Versartis Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Versartis Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}